CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-61-228-7800
Debt
Debt-to-Equity RatioN/A
Current Ratio24.42
Quick Ratio24.42
Price-To-Earnings
Trailing P/E Ratio-36.29
Forward P/E Ratio-23.87
P/E GrowthN/A
Sales & Book Value
Annual Sales$41 million
Price / Sales71.43
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book15.17
Profitability
EPS (Most Recent Fiscal Year)($1.71)
Net Income$-68,350,000.00
Net Margins-189.60%
Return on Equity-35.18%
Return on Assets-24.39%
Miscellaneous
Employees127
Outstanding Shares47,190,000
Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions
What is Crispr Therapeutics' stock symbol?
Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
How were Crispr Therapeutics' earnings last quarter?
Crispr Therapeutics AG (NASDAQ:CRSP) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.05. The firm had revenue of $1.36 million for the quarter, compared to the consensus estimate of $3.64 million. Crispr Therapeutics had a negative return on equity of 35.18% and a negative net margin of 189.60%. The company's revenue for the quarter was down 49.6% on a year-over-year basis. During the same period last year, the business posted ($0.54) EPS. View Crispr Therapeutics' Earnings History.
When is Crispr Therapeutics' next earnings date?
What price target have analysts set for CRSP?
9 analysts have issued 1-year target prices for Crispr Therapeutics' stock. Their predictions range from $51.00 to $86.00. On average, they expect Crispr Therapeutics' stock price to reach $65.1714 in the next twelve months. View Analyst Ratings for Crispr Therapeutics.
What are Wall Street analysts saying about Crispr Therapeutics stock?
Here are some recent quotes from research analysts about Crispr Therapeutics stock:
- 1. According to Zacks Investment Research, "CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. " (5/23/2018)
- 2. Cann analysts commented, "CRISPR Therapeutics presented updated preclinical data on CTX001, a CRISPR gene-editing therapy for beta-thalassemia and sickle cell disease, at the 2017 American Society of Hematology meeting. These data are highly supportive of the upcoming phase I clinical development program in beta-thalassemia, which is on track to begin in 2018." (12/10/2017)
- 3. Chardan Capital analysts commented, "We calculated the CRISPR sector enterprise value (EV) by discounting Chardan target sector EVs of companies in the AAV (assumed 3 years ahead) and small RNA (assumed 3 years ahead) gene therapy sectors; we applied a discount rate of 20%, which we believe is reasonable for preclinical biotech firms. Giving CRSP a CRISPR sector valuation distribution of 15% of the calculated CRISPR sector EV (based on our view of the firm’s relative IP weakness balanced by potential first entry of a CRISPR therapy into the clinic) and adding $272.3 mm in cash, we project a CRSP market cap range of $866 mm-$901 mm." (8/14/2017)
Who are some of Crispr Therapeutics' key competitors?
Some companies that are related to Crispr Therapeutics include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Repligen (RGEN) and Editas Medicine (EDIT).
Who are Crispr Therapeutics' key executives?
Crispr Therapeutics' management team includes the folowing people:
- Dr. Rodger Novak, Founder & Chairman (Age 51)
- Mr. Marc A. Becker, Former CFO & Sr. VP (Age 46)
- Dr. Kala Subramanian Ph.D., Chief of Staff and Sr. VP of Strategic Devel. & Operations (Age 51)
- Dr. N. Anthony Coles Jr., Sr. Advisor (Age 58)
- Dr. Samarth Kulkarni, Chief Exec. Officer (Age 39)
When did Crispr Therapeutics IPO?
(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.
Has Crispr Therapeutics been receiving favorable news coverage?
Press coverage about CRSP stock has been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Crispr Therapeutics earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 46.96 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Crispr Therapeutics' major shareholders?
Crispr Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Versant Venture Management LLC (9.77%), NEA Management Company LLC (7.39%), Abingworth LLP (4.00%), Franklin Resources Inc. (1.51%), Farallon Capital Management LLC (1.37%) and BlackRock Inc. (1.21%). Company insiders that own Crispr Therapeutics stock include Aktiengesellschaft Bayer, Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Simeon George, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Institutional Ownership Trends for Crispr Therapeutics.
Which major investors are selling Crispr Therapeutics stock?
CRSP stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Farallon Capital Management LLC, Franklin Resources Inc., Abingworth LLP, GSA Capital Partners LLP, Artal Group S.A., Trexquant Investment LP and A.R.T. Advisors LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Bradley J Phd Bolzon, Corp /De/ Celgene, Kurt Von Emster, Rodger Novak, Samarth Kulkarni, Thomas Woiwode, Tyler Dylan-Hyde and Versant Venture Capital V, LP. View Insider Buying and Selling for Crispr Therapeutics.
Which major investors are buying Crispr Therapeutics stock?
CRSP stock was acquired by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Wells Fargo & Company MN, NEA Management Company LLC, First Allied Advisory Services Inc., UBS Group AG, Victory Capital Management Inc., CIBC World Markets Inc. and EAM Global Investors LLC. Company insiders that have bought Crispr Therapeutics stock in the last two years include Aktiengesellschaft Bayer, Corp /De/ Celgene and Simeon George. View Insider Buying and Selling for Crispr Therapeutics.
How do I buy shares of Crispr Therapeutics?
Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crispr Therapeutics' stock price today?
One share of CRSP stock can currently be purchased for approximately $62.06.
How big of a company is Crispr Therapeutics?
Crispr Therapeutics has a market capitalization of $2.96 billion and generates $41 million in revenue each year. The company earns $-68,350,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Crispr Therapeutics employs 127 workers across the globe.
How can I contact Crispr Therapeutics?
Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-61-228-7800.
MarketBeat Community Rating for Crispr Therapeutics (CRSP)
MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote "Outperform" if you believe CRSP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days.
